(9ci)-beta-甲基-1H-咪唑-1-乙醇 | 191725-72-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: (9ci)-beta-甲基-1H-咪唑-1-乙醇
• 中文别名: 2,6-二氯苯甲酸；2-(1-咪唑)丙-1-醇
• 英文名称: 2-(1H-1-imidazolyl)-1-propanol
• 英文别名: 2-(Imidazol-1-yl)propan-1-ol；R-2-(imidazol-1-yl)propanol；2-(1h-Imidazol-1-yl)propan-1-ol；2-imidazol-1-ylpropan-1-ol
• CAS: 191725-72-1；68132-83-2
• 化学式: C₆H₁₀N₂O
• 分子量: 126.158
• InChiKey: ZEMKCDHZMTZUKJ-UHFFFAOYSA-N

物化性质

• 沸点：
  289.9±23.0 °C(Predicted)
• 密度：
  1.12±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.3
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  38
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2933290090

反应信息

• 作为反应物：
  描述：

  (9ci)-beta-甲基-1H-咪唑-1-乙醇 、 6-(2-imidazole-1-yl-ethoxy)-3,4-dihydro-2H-naphthalen-1-one 以there was obtained 1.63 g (49% yield) of the product as a white solid, mp 132-135° C的产率得到6-[2-(1H-1-imidazolyl)propoxy]-1,2,3,4-tetrahydro-1-naphthalenone
  参考文献：
  名称：

  Bicyclic inhibitors of protein farnesyl transferase

  摘要：

  本发明提供了公式I的化合物。本发明还提供了一种治疗癌症、治疗或预防再狭窄或动脉粥样硬化的方法。本发明还提供了一种包含公式I化合物的药学上可接受的组合物。

  公开号：

  US06265422B1
• 作为产物：
  描述：

  在 甲醇 、 potassium fluoride 作用下， 反应 3.0h， 生成 (9ci)-beta-甲基-1H-咪唑-1-乙醇
  参考文献：
  名称：

  A straightforward one-pot synthesis of biologically important imidazolyl alcohols via catalytic epoxide ring-opening reactions

  摘要：

  A general and efficient method for the preparation of biologically important imidazolyl alcohols via ring-opening of epoxides with N-silylated imidazole catalyzed by LiBr under solvent-free conditions is reported. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2012.04.019

文献信息

• Piperidine and tetrahydropyridine derivatives
  申请人：Merck Sharp & Dome Ltd.

  公开号：US05973156A1

  公开（公告）日：1999-10-26

  A class of substituted piperidine and tetrahydropyridine derivatives, linked through the 4-position thereof via an alkylene chain to a fused bicyclic heteroaromatic moiety such as indolyl, and further substituted at the 1-position by an optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl-alkyl, aryl-alkyl or heteroaryl-alkyl moiety, are selective agonists of 5-HT.sub.1 -like receptors, being potent agonists of the human 5-HT.sub.1D.spsb..alpha. receptor subtype whilst processing at least a 10-fold selective affinity for the 5-HT.sub.1D.spsb..alpha. receptor subtype relative to the 5-HT.sub.1D.spsb..beta. subtype; they are therefore useful in the treatment and/or prevention of clinical conditions, in particular migraine and associated disorders, for which a subtype-selective agonist of 5-HT.sub.1D receptors is indicated, whilst eliciting fewer side-effects, notably adverse cardiovascular events, than those associated with non-subtype-selective 5-HT.sub.1D receptor agonists.

  一类经过取代的哌啶和四氢吡啶衍生物，通过其4位点通过一条烷基链连接到融合的双环杂芳基团，如吲哚，并且在1位点进一步经过取代为一个可选择取代的烷基，烯基，炔基，环烷基-烷基，芳基-烷基或杂芳基-烷基团，是5-HT.sub.1-类受体的选择性激动剂，是人类5-HT.sub.1D.spsb..alpha.受体亚型的有效激动剂，同时相对于5-HT.sub.1D.spsb..beta.亚型至少具有10倍的选择性亲和力；因此，在治疗和/或预防临床疾病，特别是偏头痛和相关疾病方面，这些衍生物是有用的，因为这些疾病需要5-HT.sub.1D受体的亚型选择性激动剂，同时引起的副作用较少，尤其是不良心血管事件，比与非亚型选择性5-HT.sub.1D受体激动剂相关的副作用。
• Y(NO3)3·6H2O catalyzed regioselective ring opening of epoxides with aliphatic, aromatic, and heteroaromatic amines
  作者：Mayur J. Bhanushali、Nitin S. Nandurkar、Malhari D. Bhor、Bhalchandra M. Bhanage

  DOI：10.1016/j.tetlet.2008.03.152

  日期：2008.5

  Yttrium nitrate hexahydrate [Y(NO3)3·6H2O] was found to be an efficient catalyst for selective ring opening of epoxides with aliphatic, aromatic, and heteroaromatic amines at room temperature under solvent-free conditions. The system tolerated a variety of hindered and functionalized epoxides/amines and afforded the desired β-amino alcohols at low catalyst concentration.

  发现六水合硝酸钇[Y（NO 3）3 ·6H 2 O]是在室温下在无溶剂条件下与脂族，芳族和杂芳族胺选择性环氧化环氧化物的有效催化剂。该体系可耐受多种受阻和官能化的环氧化物/胺，并在低催化剂浓度下提供所需的β-氨基醇。
• [EN] DERIVATIVES OF SOBETIROME<br/>[FR] DÉRIVÉS DE SOBÉTIROME
  申请人：UNIV OREGON HEALTH & SCIENCE

  公开号：WO2016134292A1

  公开（公告）日：2016-08-25

  Ester derivatives of sobetirome with enhanced CNS distribution are disclosed.

  公开了具有增强的中枢神经系统分布的索贝曲罗甲酯衍生物。
• Disphosphonic acid derivatives, processes for their production and
  申请人：Boehringer Mannheim, GmbH

  公开号：US05206253A1

  公开（公告）日：1993-04-27

  The present invention concerns novel disphosphonates having the general formula I ##STR1## in which Het represents a heterocyclic five-membered ring with 2-4 heteroatoms which is substituted, if desired, and which can also be partially hydrogenated, R.sub.1 -R.sub.7 each denote, independently of each other, hydrogen or C.sub.1 -C.sub.5 alkyl, X=denotes hydrogen, OH or the group --NR.sub.8 R.sub.9, in which R.sub.8 and R.sub.9 should each be, independently of each other, hydrogen or C.sub.1 -C.sub.5 alkyl, m and n denote, independently of each other, 0, 1 or 2, as well as their pharmacologically safe salts and optically active forms.

  本发明涉及具有一般式I的新型二磷酸酯化合物 其中Het代表带有2-4个杂原子的杂环五元环，如有需要，可以取代，并且也可以是部分氢化的，R.sub.1 -R.sub.7各自独立地表示氢或C.sub.1 -C.sub.5烷基，X=表示氢、OH或基团--NR.sub.8 R.sub.9，其中R.sub.8和R.sub.9各自独立地表示氢或C.sub.1 -C.sub.5烷基，m和n各自独立地表示0、1或2，以及它们的药理学安全盐和光学活性形式。
• DERIVATIVES OF SOBETIROME
  申请人：Scanlan Thomas S.

  公开号：US20160244418A1

  公开（公告）日：2016-08-25

  Ester derivatives of sobetirome with enhanced CNS distribution are disclosed.

  本发明公开了具有增强中枢神经系统分布的Sobetirome的Ester衍生物。